The pharmaceutical development business is led by our subsidiary, EPS Medical Consultancy (Japan) Co., Ltd., and we aim to create a specialized healthcare trading company that connects Japan and China. The business contents of the Pharmaceutical Development Business are as follows.
EPS Medical Consultancy (Japan) Co., Ltd. : https://eps-medicalconsultancy.co.jp/
The Japan-China specialized CRO will provide clinical trial-related services in China for Japanese pharmaceutical companies. Our strength is that our project managers, who speak Japanese and Chinese who speak Japanese and Chinese manage the entire study, connecting Japanese clients and Chinese operations.
The licensing and financing support business introduces promising drug candidates born from academia and startups in Japan to overseas companies and supports fund raising and overseas expansion. In collaboration with Japan-China Medical Communication Center, we will also contribute to medical exchange businesses between Japan and China (training, promotional activities, support for participation in overseas exhibitions, etc.).
The IRO business supports drug discovery startups and academia in Japan for planning, development, and launch strategies, including non-clinical studies, clinical trials, application for approval, manufacturing and sales. We also support companies engaged in research and development of drugs, medical devices, regenerative medicine, health foods, and other products in China and other Asian countries with planning, development, and launch strategies, including non-clinical studies, clinical trials, approval applications, manufacturing, and sales in connection with the entry into Japanese market.